vTv Therapeutics, Inc. Class A Forecast, price target & analysts
vTv Therapeutics, Inc. Class A Target price 2026 - Analyst rating & recommendation
vTv Therapeutics, Inc. Class A Classifications & Recommendation
vTv Therapeutics, Inc. Class A Price Target
| Target Price | $58.14 |
| Price | $30.73 |
| Potential |
89.20%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target vTv Therapeutics, Inc. Class A 2027 .
The average vTv Therapeutics, Inc. Class A target price is $58.14.
This is
89.20%
register free of charge
$70.35
128.93%
register free of charge
$42.42
38.04%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend vTv Therapeutics, Inc. Class A to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the vTv Therapeutics, Inc. Class A stock has an average upside potential 2027 of
89.20%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 30.42 |
| 100.00% |
7 Analysts have issued a sales forecast vTv Therapeutics, Inc. Class A 2026 . The average vTv Therapeutics, Inc. Class A sales estimate is
This results in the following potential growth metrics:
7 vTv Therapeutics, Inc. Class A Analysts have issued a net profit forecast 2026. The average vTv Therapeutics, Inc. Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.20 | -2.00 |
| 0.00% | 37.50% | |
| P/E | negative | |
| EV/Sales | 1.24 |
7 Analysts have issued a vTv Therapeutics, Inc. Class A forecast for earnings per share. The average vTv Therapeutics, Inc. Class A EPS is
This results in the following potential growth metrics and future valuations:
vTv Therapeutics, Inc. Class A...
Current vTv Therapeutics, Inc. Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Mar 12 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Mar 11 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jan 27 2026 |
| Roth Capital |
Locked
➜
Locked
|
Locked | Jan 23 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jan 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Mar 12 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Mar 11 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jan 27 2026 |
|
Locked
Roth Capital:
Locked
➜
Locked
|
Jan 23 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jan 05 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
